Dupilumab Treatment Reduces Hospitalizations in Adults with Moderate-to-Severe Atopic Dermatitis

Authors

Jonathan I. Silverberg, Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC.
Norma P. Rubini, School of Medicine and Surgery, Federal University of the State of Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil.
Mario C. Pires, Dermatology Service, Hospital do Servidor Público Estadual de São Paulo, São Paulo, Brazil.
Ana B. Rossi, Sanofi Genzyme, Cambridge, Mass.
Annie Zhang, Sanofi Genzyme, Cambridge, Mass.
Zhen Chen, Regeneron Pharmaceutical, Inc., Tarrytown, NY.
Noah A. Levit, Regeneron Pharmaceutical, Inc., Tarrytown, NY.
Jingdong Chao, Regeneron Pharmaceutical, Inc., Tarrytown, NY.
Brad Shumel, Regeneron Pharmaceutical, Inc., Tarrytown, NY.
Gaëlle Bégo-Le Bagousse, Sanofi Chilly Mazarin, Chilly Mazarin, France. Electronic address: Gaelle.Le-Bagousse-Bego@sanofi.com.

Document Type

Journal Article

Publication Date

1-12-2022

Journal

The journal of allergy and clinical immunology. In practice

DOI

10.1016/j.jaip.2021.11.034

Keywords

Atopic dermatitis; Dupilumab; Flares; Hospitalization; Resource utilization

Abstract

BACKGROUND: Refractory disease, flares, or infections in atopic dermatitis (AD) can lead to hospitalizations. OBJECTIVE: To compare hospitalization rates among adults with moderate-to-severe AD treated with dupilumab versus control. METHODS: Data from 7 randomized, placebo-controlled trials of dupilumab (300 mg every 2 weeks [q2w] and/or weekly [qw]; with or without topical corticosteroids) were analyzed. RESULTS: Patients in the dupilumab 300 mg q2w, qw, and combined dupilumab (q2w and qw; n = 1,841) groups compared with patients in the control group (n = 1,091) had lower rates of all-cause hospitalizations (5.8, 2.7, and 3.8 events, respectively, vs 9.0 events per 100 patient-years [PY]; all P < .05 [49%, 71%, and 62% risk reduction, respectively]); AD-related hospitalizations (2.0, 0.4, 1.0 events vs 4.1 events per 100 PY; P < .05 for qw and dupilumab combined [91% and 79% risk reduction, respectively]); as well as reduced overall duration of AD-related hospitalization (10.9, 7.3, and 8.6 d vs 38.9 d per 100 PY). CONCLUSIONS: Among adults with moderate-to-severe AD, treatment with dupilumab versus control was associated with significant reductions in all-cause and AD-related hospitalization rates, and shorter duration of AD-related hospitalization.

APA Citation

Silverberg, Jonathan I.; Rubini, Norma P.; Pires, Mario C.; Rossi, Ana B.; Zhang, Annie; Chen, Zhen; Levit, Noah A.; Chao, Jingdong; Shumel, Brad; and Bégo-Le Bagousse, Gaëlle, "Dupilumab Treatment Reduces Hospitalizations in Adults with Moderate-to-Severe Atopic Dermatitis" (2022). GW Authored Works. Paper 267.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/267

Department

Dermatology